Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Log in to your Inderes Free account to see all free content on this page.
Create account

DanCann Pharma

0.48 DKK

+8.11 %

Less than 1K followers

DANCAN

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Investor consensus
Compare
+8.11 %
+77.78 %
-41.10 %
-65.96 %
-76.00 %
-86.67 %
-99.80 %
-99.94 %
-99.94 %

DanCann Pharma is a Danish life science company focused on discovering, developing, manufacturing, and commercialization of novel cannabinoid therapeutic products for medical use. The company was founded in 2018 due to the poor access for cannabinoid-based drugs and pharmaceuticals and with the purpose of developing and supplying medical cannabis, with a focus on consistency and quality provided by state-of-the-art and newly constructed manufacturing facilities (called Biotech Pharm1) which expect to be approved by the Danish authorities during 2022. DanCann recently acquired the Danish distributor of medical cannabis products, CannGros after which DanCann is now a fully vertical integrated operator within the market of cannabis for medical use, having development, manufacturing, and commercialization capabilities in-house.

Read more
Market cap
1.92M DKK
Turnover
2.93K DKK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

All
Research
Webcasts
Press releases
ShowingAll content types
Regulatory press release11/17/2025, 4:01 PM

DanCann Pharma A/S Completes Sale of CannGros ApS to StenoCare A/S through Equity Transaction

DanCann Pharma
Regulatory press release10/27/2025, 5:00 PM

DanCann Pharma A/S delivers Q3 2025 Highlights - Leadership Transition, Strategic Progress, and Path Toward Delisting

DanCann Pharma
Regulatory press release10/21/2025, 8:00 AM

Minutes of Extraordinary General Meeting held in DanCann Pharma A/S

DanCann Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Regulatory press release10/6/2025, 4:05 PM

DanCann Pharma A/S: Chairman's Letter to the Shareholders - CEO Transition and Voluntary Delisting

DanCann Pharma
Regulatory press release10/6/2025, 4:01 PM

DanCann Pharma: NOTICE OF EXTRAORDINARY GENERAL MEETING IN DANCANN PHARMA A/S

DanCann Pharma
Regulatory press release10/6/2025, 4:00 PM

DanCann Pharma A/S has resolved to apply for delisting from Spotlight Stock Market, subject to approval by the general meeting

DanCann Pharma
Regulatory press release8/25/2025, 5:00 PM

DanCann Pharma A/S: Delivers Q2-2025 Highlights

DanCann Pharma
Regulatory press release7/9/2025, 8:15 PM

DanCann Pharma A/S shares supplementary details of the obtained bridge loan

DanCann Pharma
Regulatory press release7/9/2025, 9:00 AM

DanCann Pharma A/S signs a conditional sales agreement for the sale of manufacturing site (BP1), secures bridge financing, and launches new strategy, Maturity2028

DanCann Pharma
Regulatory press release5/23/2025, 3:05 PM

DanCann Pharma A/S: Delivers Q1-2025 Highlights - Expands Prescription (Rx) Portfolio, Eyes Consumer Health Market Entry (OTC)

DanCann Pharma
Regulatory press release5/23/2025, 3:05 PM

DanCann Pharma A/S: Præsenterer højdepunkter fra 1. kvartal 2025 - Udvider receptportefølje (Rx) og forbereder indtræden på markedet for håndkøbsprodukter (OTC)

DanCann Pharma
Regulatory press release5/19/2025, 6:30 AM

DanCann Pharma A/S: Receives Regulatory Approval for Bedrolite® and Bedrobinol® from the Danish Medicines Agency under the Danish Pilot Programme

DanCann Pharma
Regulatory press release4/25/2025, 6:45 AM

DanCann Pharma A/S: Adoption of Permanent Medicinal Cannabis Legislation in Denmark Completed

DanCann Pharma
Regulatory press release4/24/2025, 9:30 AM

DanCann Pharma A/S: Updated Financial Calendar for the Remainder of 2025

DanCann Pharma
Regulatory press release4/24/2025, 9:15 AM

DanCann Pharma: DANCANN PHARMA A/S: MINUTES OF ANNUAL GENERAL MEETING

DanCann Pharma
Regulatory press release4/4/2025, 3:50 PM

DanCann Pharma A/S: Notice of Annual General Meeting in DanCann Pharma A/S

DanCann Pharma
Regulatory press release4/4/2025, 3:45 PM

DanCann Pharma A/S Releases 2024 Annual Report Highlighting Growth and Operational Efficiency

DanCann Pharma
Regulatory press release3/27/2025, 7:00 PM

DanCann Pharma A/S: Postponement of release of annual report 2024 and AGM 2025

DanCann Pharma
Regulatory press release3/13/2025, 12:00 PM

DanCann Pharma A/S forges cutting edge alliance with Tetra Pharm Technologies ApS

DanCann Pharma
Regulatory press release2/18/2025, 1:15 PM

DanCann Pharma A/S: Completion of reverse share split and redemption of shares

DanCann Pharma
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.